Burzynski Research Institute, Inc.

Equities

BZYR

US1231591058

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:38:16 08/05/2024 pm IST			5-day change	1st Jan Change
0.044 ^USD	+2.92%		0.00%	0.00%

16/01	Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023	CI
2023	Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023	CI

BURZYNSKI RESEARCH INSTITUTE INC : Change in Directors or Principal Officers (form 8-K)

April 07, 2023 at 02:59 am IST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

On April 6, 2023, Carlton Hazlewood, a member of the board of directors (the "Board") of Burzynski Research Institute, Inc. (the "Company"), notified the Company of his decision to resign from the Board effective immediately. Mr. Hazlewood's decision to resign is for personal reasons and not related to any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

Latest news about Burzynski Research Institute, Inc.

Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023	17/01	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023	13/23/13	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2023	14/23/14	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 28, 2023	26/23/26	CI
Burzynski Research Institute, Inc. Enters into A License Agreement with Dr. Stanislaw R. Burzynski	23/23/23	CI
Burzynski Research Institute, Inc. Announces Resignation of Carlton Hazlewood from the Board	07/23/07	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2022	14/23/14	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2022	14/22/14	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2022	15/22/15	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 28, 2022	27/22/27	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2021	15/22/15	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter Ended August 31, 2021	16/21/16	CI
Burzynski Research Institute, Inc Announces Board Changes	07/21/07	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 28, 2021	25/21/25	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter Ended November 30, 2020	15/21/15	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter Ended August 31, 2020	16/20/16	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2020	16/20/16	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 29, 2020	29/20/29	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter Ended November 30, 2019	15/20/15	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Second Quarter Ended August 31, 2019	16/19/16	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2019	16/19/16	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Full Year Ended February 28, 2019	30/19/30	CI
Burzynski Research Institute, Inc. Reports Earnings Results for the Third Quarter Ended November 30, 2018	15/19/15	CI
Burzynski Research Institute, Inc. Announces the Launch of a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma	14/16/14	CI
Burzynski Research Institute, Inc. Announces Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Primary Brain Tumors - Final Report (Protocol Bt-09)	08/15/08	CI

Chart Burzynski Research Institute, Inc.

Duration

Period

Chart Burzynski Research Institute, Inc.

More charts

Company Profile

Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids, which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and is reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. The Company conducted all the Phase II clinical trials for the treatment of a variety of cancers using the combination of Antineoplastons A10 and AS2-1. Most of the trials involve the use of intravenous formulations of Antineoplastons; however, a few trials use oral formulations. The Company has not generated any operating revenue since its inception. The Company's clinical trials are conducted at the Burzynski Clinic.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BURZYNSKI RESEARCH INSTITUTE, INC.	0.00%	5.78M
MODERNA, INC.	+29.77%	49.18B
IQVIA HOLDINGS INC.	+1.00%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.71B
BIO-TECHNE CORPORATION	+8.22%	13.26B
MEDPACE HOLDINGS, INC.	+32.41%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.99B

Other Biotechnology & Medical Research